| Document Date: 2013-09-27 12:02:35
Open Document File Size: 330,74 KBShare Result on Facebook
City Spokane / Angeles / Scottsdale / Nashville / Waltham / / Company 5Tesaro Inc / / Continent America / / Country United Kingdom / / Event FDA Phase / / Facility Oschin Comprehensive Cancer Institute / Stable Disease / Piper Cancer Center / Cedars Sinai Medical Center / / MedicalCondition ALK-dependent tumor / cancers / ALK+ tumor / leukemia / tumor / cancer / colorectal and pancreatic cancers / neuroblastoma and inflammatory myofibroblastic tumors / lymphoma / tumors / disease / NSCLC / Pancreatic Papillary Thyroid Ovarian Carcinoid / solid tumor / solid tumors / thyroid and pancreatic cancer / Peripheral Neuropathy / lymphoma kinase / Fatigue / lung cancer / anaplastic large cell lymphoma / non-small cell lung cancer / Stable Disease / naturally-occurring TRKA-rearranged colorectal cancer / anaplastic lymphoma kinase / pleural disease / ALK- or TRK-positive tumors / / Organization 2Virginia G. Piper Cancer Center / Comprehensive Cancer Institute / Cedars Sinai Medical Center / 3Sarah Cannon Research Institute / / Person Keith Wilcoxen / / Position **Investigator / / Product RL / TSR-011 / / ProvinceOrState Tennessee / California / Arizona / Massachusetts / / Technology pharmacokinetics / /
SocialTag |
ESMOTSR-011, A Potent ALK Inhibitor with Clinical Activity in Phase I/IIa Development Glen J Weiss1, Jasgit C Sachdev2, Jeffrey R Infante3, Monica Mita4, Keith M Wilcoxen5, Vikram Kansra5, David G Brooks5, Robert